A Phase I, Randomized, Double-Blind, Placebo-Controlled, Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of Orally Administered PRN2246 in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 09 Jun 2018
At a glance
- Drugs PRN-2246 (Primary)
- Indications Autoimmune disorders; CNS disorders; Inflammation; Multiple sclerosis
- Focus Adverse reactions; First in man
- 30 Apr 2018 Planned End Date changed from 31 May 2018 to 15 Aug 2018.
- 07 Feb 2018 Status changed from not yet recruiting to recruiting, according to a sanofi media release.
- 18 Oct 2017 New trial record